4CPS-043 Efficacy and safety of anti-calcitonin gene-related peptide monoclonal antibodies for migraine prophylaxis: one-year real-life experience

L Estrada; G Cardona Peitx; L Dorado Bouix; S Marin; E Terricabras Mas; A Bocos-Baelo; C García-Castiñeira; S Garcia-Xipell; C Rodríguez-González; C Quiñones

doi:10.1136/ejhpharm-2024-eahp.147

Article info

Section 4: Clinical pharmacy services

4CPS-043 Efficacy and safety of anti-calcitonin gene-related peptide monoclonal antibodies for migraine prophylaxis: one-year real-life experience

Authors

L Estrada Hospital Universitari Germans Trias I Pujol, Pharmacy Department, Badalona, Spain PubMed articles Google scholar articles
G Cardona Peitx Hospital Universitari Germans Trias I Pujol, Pharmacy Department, Badalona, Spain PubMed articles Google scholar articles
L Dorado Bouix Hospital Universitari Germans Trias I Pujol, Pharmacy Department, Badalona, Spain PubMed articles Google scholar articles
S Marin Hospital Universitari Germans Trias I Pujol, Pharmacy Department, Badalona, Spain PubMed articles Google scholar articles
E Terricabras Mas Hospital Universitari Germans Trias I Pujol, Pharmacy Department, Badalona, Spain PubMed articles Google scholar articles
A Bocos-Baelo Hospital Universitari Germans Trias I Pujol, Pharmacy Department, Badalona, Spain PubMed articles Google scholar articles
C García-Castiñeira Hospital Universitari Germans Trias I Pujol, Pharmacy Department, Badalona, Spain PubMed articles Google scholar articles
S Garcia-Xipell Hospital Universitari Germans Trias I Pujol, Pharmacy Department, Badalona, Spain PubMed articles Google scholar articles
C Rodríguez-González Hospital Universitari Germans Trias I Pujol, Pharmacy Department, Badalona, Spain PubMed articles Google scholar articles
C Quiñones Hospital Universitari Germans Trias I Pujol, Pharmacy Department, Badalona, Spain PubMed articles Google scholar articles

Citation

Estrada L, Cardona Peitx G, Dorado Bouix L, et al

4CPS-043 Efficacy and safety of anti-calcitonin gene-related peptide monoclonal antibodies for migraine prophylaxis: one-year real-life experience

European Journal of Hospital Pharmacy 2024;31:A72.

Publication history

First published March 20, 2024.

Online issue publication

March 20, 2024

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Main menu

Authors

Citation

Publication history

Request permissions

Copyright information

Log in using your username and password

Main menu

Log in using your username and password

You are here

Authors

Citation

Publication history

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password